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Abstract
Aim: To determine the clinical features of vernal keratoconjunctivitis and to 
evaluate the safety and the efficacy of the medical treatment on clinical 
grades. Material and Method: All patients with vernal keratoconjunctivitis 
who had been treated with mast-cell stabilizers, antihistamines and artificial 
tear drops previously were enrolled in the study. Topical steroids were added 
during recurrences, were tapered and discontinued according to the clinical 
improvement. Topical cyclosporin 0.05% four times daily was used additio-
nally in cases of inadequate response to treatment or evident steroid depen-
dance. Main outcome measures were the clinical features, change of clini-
cal grades, response to treatment, rate of recurrences and side effects of the 
eyedrops. Results: Twenty patients ( 13 males, 7 females) with vernal kera-
toconjunctivitis in different severity scales were included. The median age of 
the patients was 10 (9-11) years. The median follow-up time was 35 (15-56) 
months. Ten patients received topical cyclosporine. The rate of recurrences 
was similar in patients who received topical cyclosporine compared to those 
who were followed with topical steroids. (p=0.17) No severe adverse reaction 
to any of the formulations was seen. Discussion: Topical 0.05% cyclosporin is 
safe and effective for the treatment of vernal keratoconjunctivitis as a stero-
id sparing agent. It helps to obtain good clinical response without serious ad-
verse effects and provides improvement on the clinical grades. 
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Özet
Amaç: Vernal keratokonjonktivitin klinik özelliklerini tanımlamak ve tıbbi te-
davinin güvenlik ve klinik evreler üzerindeki etkinliğini değerlendirmek. Gereç 
ve Yöntem: Vernal keratokonjonktivit tanısı olan ile topikal mast hücre sta-
bilizatörü, antihistaminik  ve suni gözyaşı tedavisi alan hastalar çalışmaya 
dahil edildi. Topikal steroidler nüksler sırasında eklendi, klinik düzelmeye göre 
azaltıldı ve kesildi. Topikal siklosporin % 0,05 günde dört kez bir damla olarak 
steroid direnci olan veya tedaviye yetersiz yanıtı olan hastalarda kullanıldı. 
Temel sonuç kriterleri klinik özellikler, klinik evrelerde değişiklik, nüks sıklığı 
ve göz damlalarının yan etkileriydi. Bulgular: Değişik klinik evrelerde vernal 
keratokonjonktivit tanısı olan 20 hasta (13 erkek, 7 kız) çalışmaya dahil edildi. 
Ortanca hasta yaşı 10 (9-11) yıl idi. Ortanca takip süresi 35 (15-56) ay idi. 
On hasta topikal siklosporin kullandı. Topikal siklosporin kullanan hastalarda 
nüks sıklığı topikal steroid kullananlar ile benzer idi. (p=0.17) Hiçbir formüla-
syona karşı ciddi yan etki izlenmedi. Tartışma: Topikal siklosporin %0,05 ste-
roidden koruyucu bir ilaç olarak vernal keratokonjonktivit tedavisinde güvenli 
ve etkilidir. Ciddi yan etki olmadan iyi bir klinik cevap alınmasına yardımcı 
olur ve klinik evrelerin düzelmesini sağlar. 
Anahtar Kelimeler
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Introduction
Vernal keratoconjunctivitis (VKC) is a debilitating ocular disease 
with chronic course which affects mostly the children in their 
first decade of life [1]. Characteristic clinical features consist 
of papillae on the upper tarsal conjunctiva, limbal infiltrates, 
copious discharge and corneal involvement such as punctate 
keratitis, epithelial erosions and shield ulcers [2]. Severe cor-
neal involvement and conjunctival cicatrization may be sight-
threatening. Many studies have made attempts to elucidate the 
complex immunopathogenesis of VKC in order to define succes-
ful treatment methods providing good clinical outcomes before 
the development of vision compromising secondary side effects. 
The pathogenesis of VKC is multifactorial. Many types of cells 
such as mast cells, lymphocytes, eosinophils, cytokines and also 
neuroendocrinological factors may be involved. Topical steroids 
are generally preferred during exacerbation of the disease in or-
der to control the inflammation and provide a certain amount of 
local immunosuppression. However, corneal infections, second-
ary glaucoma and cataract are among the probable side effects. 
Therefore, topical cyclosporine which mainly limits antigen de-
pendent T cell activation, is being used as an immunomodula-
tor to reduce mentioned side effects and salvage from steroid 
dependance. 
In  the  present  nonrandomized  prospective  study,  we  aimed 
to define the clinical features of VKC in a sample of patients 
among whom some had received topical cyclosporine as an ad-
ditional treatment and to evaluate the efficacy and the side ef-
fects of the treatment protocole and to determine the change 
of clinical severity during follow-up.
Material and Method
The study was conducted at the department of Ophthalmology, 
Cukurova University School of Medicine, Adana upon approval 
of institutional review board. Written informed consent was ob-
tained from all patients. Twenty patients with a diagnosis of 
VKC were enrolled in the study. None of the patients had neither 
worn contact lenses nor received topical steroid or cyclosporine 
previously but were receiving topical mast cell stabilizers and 
antihistamines. 
The clinical picture of the patients were graded at initial and the 
final visits according to the grading system which was previous-
ly suggested and introduced by Bonini et al. [3]. Topical steroids 
(Prednisolone acetate 1%) were added during exacerbation of 
the disease, tapered and stopped after definite control of the 
disease. Topical cyclosporine 0.05% (Restasis®) was added for 
patients who were considered as steroid dependent or unre-
sponsive to steroids according to the clinician’s opinion. 
Main outcome measures of the study were the efficacy and 
safety  of  the  treatment,  effect  of  the  treatment  on  clinical 
grades  and  rate  of  recurrences.  Grades  were  obtained  from 
each patient at the beginning and at the end of the study.
Statistical analyses were performed using SPSS software for 
Windows version 15.0 (Statistical Package for the Social Sci-
ences, SPSS, Inc., Chicago, IL). Arithmetic mean, standard de-
viations,  median,  range,  frequency  were  used  as  descriptive 
statistics.  For  normal  distribution  of  the  quantitative  data, 
independent samples t test was used for comparison of two 
independent groups. Results were accepted as statistically sig-
nificant when p was <0.05.
Results
Twenty patients (13 males, 7 females) who had the diagnosis 
of VKC were enrolled in the study. All patients were given topi-
cal antihistamines, mast cell stabilizers and artificial tear drops 
before the study. Topical steroids (prednisolone acetate 1% ) 
were added during recurrences, tapered and discontinued after 
alleviation of the inflammation. 
During follow-up topical cyclosporine A 0.05% four times daily 
was used for 10 patients whose clinical situation was thought 
to be steroid dependent or resistant. Of these 10 patients, eight 
had severe exacerbations which were treated succesfully with 
topical steroids but relapsed during every tapering period of the 
steroids, and two patients were considered as having steroid 
resistance because of inadequate clinical response to topical 
steroids. Under cover of topical cyclosporine, topical steroids 
were tapered and discontinued safely without triggering a new 
recurrence. The median age of the patients was 10 years (9-11), 
and the median follow-up time was 35 (15-56) months. There 
was no significant difference of gender and age between pa-
tients who received topical cyclosporine or only topical steroids. 
None of the patients had associated ocular or systemic disease 
besides VKC and none had a history of previous ocular surgery.
The median number of recurrences was 3 (2-5) for patients who 
received topical steroids and 2 (1-3) for patients who received 
topical cyclosporine. (p=0.17) 
No serious side effects related to topical medication were en-
countered during the follow-up period besides a transient in-
traocular pressure elevation in a patient who received topical 
steroids for 4 weeks which was controlled with topical antiglau-
comatous eyedrops. The clinical grades were improved for all 
patients during follow-up. (Tablo 1 and Figure 1)
Discussion
VKC is characterized with bilateral inflammation of ocular and 
periocular tissue in response to ocular allergic stimulus and is 
commonly seen in male pediatric population. The presence of 
associated allergic diseases in many patients with VKC points 
a common underlying immunological process where Th2-driven, 
IgE dependent and independent pathways are involved [4]. Type 
I and IV hypersensitivity reactions are involved in VKC. Antigen 
presenting cells such as Langerhan’s cells, Th2 cells, B cells ex-
pressing CD21, CD23 and CD40 and IL-8 have particular impor-
tance during multifactorial pathogenesis of VKC [5].
The primary treatment measures include avoidance from the 
allergens. The secondary measures consist of topical decon-
Table 1. Clinical grades of the patients at the beginning and at the end of the 
study
Clinical Grade Initial (No. of patients) Final (No. of patients)
Cyc (+)* Cyc (-)** Cyc (+)* Cyc (-)**
Grade I 1 1 7 5
Grade IIA 1 1 2 4
Grade IIB 2 2 1 1
Grade III 3 3 - -
Grade IV 3 3 - -
*Patients who received topical cyclosporine 0.05% during follow-up.
**Patients who were treated without topical cyclosporine 0.05%.
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gestants, antihistamines, mast cell stabilizing agents and an-
tiinflamatory agents. Furthermore, topical immunomodulatory 
agents and immunotherapy are also introduced for the treat-
ment of various types of ocular allergy [6]. Even though topical 
steroids are still the most effective agents during exacerbation 
of the disease, their severe ocular side effects limit their use 
[7;8].
Cyclosporine which was isolated from Tolypocladium inflatum 
Gams acts is a cyclic polypeptide calcineurin inhibitor which 
inhibits primarily the action of T cells through downregulation 
of expression of IL-2 receptors [9;10]. It also displays as an in-
hibitor of histamine release, and early phase reaction in type-
I allergy, and reduces conjunctival fibroblast proliferation rate 
[11;12]. Cyclosporine was also showed to be effective in reduc-
ing eosinophilic infiltration by interfering type IV allergic reac-
tion in conjunctiva [13]. The efficacy of topical cyclosporine in 
the treatment of VKC is controversial. Many studies showed the 
high efficacy of topical cyclosporine in VKC [14-17]. However, 
Daniell et al.[18] evaluated the efficacy, safety and therapeu-
tic effect of topical cyclosporine A in steroid dependent allergic 
conjunctivitis and showed that it had no benefit over placebo 
as a steroid sparing agent. However, in the present study we 
found that topical cyclosporine may provide similar frequency 
of recurrences compared to topical steroids. 
Hingorani et al.[19] investigated the immunomodulatory effect 
of topical cyclosporine A after 3 months of treatment through 
superior tarsal conjunctiva specimens. They found that the in-
crease of T cells which express IL-2 and IFNγ, and the decrease 
in CD4-CD8 ratio which indicated the potential effect of topical 
cyclosporine on ocular immune profile. 
Keklikci  et  al.  [20]  demonstrated  that  topical  cyclosporine  A 
0.05% caused a significant decrease of conjunctival inflamma-
tory cell count by using conjunctival impression cytology.
The present study should be considered in the context of its 
following limitations: the nonrandomized nature of the study, 
small number of patients, short follow-up period and lack of 
immunological investigation. However, we investigated the ef-
ficacy of topical cyclosporine 0.05% as a steroid sparing agent 
in patients who were considered as steroid dependent or resis-
tant, and we found that topical cyclosporine was effective in the 
treatment of VKC.
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Figure 1. Clinical picture of a patient with VKC  showing giant papillae before 
treatment(A). Clinical picture of the same patient after two cycles of topical ste-
roid treatment followed by topical cyclosporine 0.05% (3 months after the initial 
presentation) (B).
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